Isabelle Peguillet

Isabelle Peguillet

Auto-generated profile, based on publicly available information

Isabelle Peguillet

Gustave Roussy, Villejuif, France

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
AGAnne-Gaëlle Goubet
Anne-Gaëlle Goubet
LLLeonardo Lordello
Leonardo Lordello
CSCarolina Alves Costa Silva
Carolina Alves Costa Silva
IPIsabelle Peguillet
Isabelle Peguillet
MGMarianne Gazzano
Marianne Gazzano
YLYohann Loriot
Yohann Loriot
Biomarkers guiding the neoadjuvant use of immune-checkpoint blockers (ICB) are needed for patients with localized muscle-invasive bladder cancers (MIBC). Profiling tumor and blood samples, we found that follicular helper CD4+ T cells (TFH) are among the best therapeutic targets of pembrolizumab correlating with progression-free survival. TFH were associated with tumoral CD8 and PD-L1 expression at baseline and the induction of tertiary lymphoid structures after pembrolizumab. Blood central memory TFH accumulated in tumors where they produce CXCL13, a chemokine found in the plasma of responders only. IgG4+CD38+ TFH residing in bladder tissues correlated with clinical benefit. Finally, TFH and IgG directed against urothelium-invasive Escherichia coli dictated clinical responses to pembrolizumab in three independent cohorts. The links between tumor infection and success of ICB immunomodulation should be prospectively assessed at a larger scale. Significance: In patients with bladder cancer treated with neoadjuvant pembrolizumab, E. coli–specific CXCL13 producing TFH and IgG constitute biomarkers that predict clinical benefit. Beyond its role as a biomarker, such immune responses against E. coli might be harnessed for future therapeutic strategies. This article is highlighted in the In This Issue feature, p. 2221

4 April 2023
Verified
Other
Open access
AGAnne-Gaëlle Goubet
Anne-Gaëlle Goubet
LLLeonardo Lordello
Leonardo Lordello
CSCarolina Alves Costa Silva
Carolina Alves Costa Silva
IPIsabelle Peguillet
Isabelle Peguillet
MGMarianne Gazzano
Marianne Gazzano
YLYohann Loriot
Yohann Loriot
Biomarkers guiding the neoadjuvant use of immune-checkpoint blockers (ICB) are needed for patients with localized muscle-invasive bladder cancers (MIBC). Profiling tumor and blood samples, we found that follicular helper CD4+ T cells (TFH) are among the best therapeutic targets of pembrolizumab correlating with progression-free survival. TFH were associated with tumoral CD8 and PD-L1 expression at baseline and the induction of tertiary lymphoid structures after pembrolizumab. Blood central memory TFH accumulated in tumors where they produce CXCL13, a chemokine found in the plasma of responders only. IgG4+CD38+ TFH residing in bladder tissues correlated with clinical benefit. Finally, TFH and IgG directed against urothelium-invasive Escherichia coli dictated clinical responses to pembrolizumab in three independent cohorts. The links between tumor infection and success of ICB immunomodulation should be prospectively assessed at a larger scale.Significance:In patients with bladder cancer treated with neoadjuvant pembrolizumab, E. coli–specific CXCL13 producing TFH and IgG constitute biomarkers that predict clinical benefit. Beyond its role as a biomarker, such immune responses against E. coli might be harnessed for future therapeutic strategies.This article is highlighted in the In This Issue feature, p. 2221

4 April 2023
Verified
Other
Open access
AGAnne-Gaëlle Goubet
Anne-Gaëlle Goubet
LLLeonardo Lordello
Leonardo Lordello
CSCarolina Alves Costa Silva
Carolina Alves Costa Silva
IPIsabelle Peguillet
Isabelle Peguillet
MGMarianne Gazzano
Marianne Gazzano
YLYohann Loriot
Yohann Loriot
Supplementary Figure from Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer

4 April 2023
Verified
Other
Open access
AGAnne-Gaëlle Goubet
Anne-Gaëlle Goubet
LLLeonardo Lordello
Leonardo Lordello
CSCarolina Alves Costa Silva
Carolina Alves Costa Silva
IPIsabelle Peguillet
Isabelle Peguillet
MGMarianne Gazzano
Marianne Gazzano
YLYohann Loriot
Yohann Loriot
Biomarkers guiding the neoadjuvant use of immune-checkpoint blockers (ICB) are needed for patients with localized muscle-invasive bladder cancers (MIBC). Profiling tumor and blood samples, we found that follicular helper CD4+ T cells (TFH) are among the best therapeutic targets of pembrolizumab correlating with progression-free survival. TFH were associated with tumoral CD8 and PD-L1 expression at baseline and the induction of tertiary lymphoid structures after pembrolizumab. Blood central memory TFH accumulated in tumors where they produce CXCL13, a chemokine found in the plasma of responders only. IgG4+CD38+ TFH residing in bladder tissues correlated with clinical benefit. Finally, TFH and IgG directed against urothelium-invasive Escherichia coli dictated clinical responses to pembrolizumab in three independent cohorts. The links between tumor infection and success of ICB immunomodulation should be prospectively assessed at a larger scale.Significance:In patients with bladder cancer treated with neoadjuvant pembrolizumab, E. coli–specific CXCL13 producing TFH and IgG constitute biomarkers that predict clinical benefit. Beyond its role as a biomarker, such immune responses against E. coli might be harnessed for future therapeutic strategies.This article is highlighted in the In This Issue feature, p. 2221

4 April 2023
Verified
Other
Open access
AGAnne-Gaëlle Goubet
Anne-Gaëlle Goubet
LLLeonardo Lordello
Leonardo Lordello
CSCarolina Alves Costa Silva
Carolina Alves Costa Silva
IPIsabelle Peguillet
Isabelle Peguillet
MGMarianne Gazzano
Marianne Gazzano
YLYohann Loriot
Yohann Loriot
Supplementary Figure from Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer